Search

Displaying results 8841 - 8850 of 10000 in total
  1. Drug

    Polydioxanone

    go.drugbank.com/drugs/DB14832
    Investigational

    Polydioxanone is under investigation in clinical trial NCT00998907 (PDS*Plus and Wound Infections After Laparotomy).

  2. Drug

    Tarloxotinib

    go.drugbank.com/drugs/DB14944
    Investigational

    Tarloxotinib is under investigation in clinical trial NCT03743350 (NSCLC Exon 20 or HER2-activating Mutations).

  3. Drug

    Naphthoquine

    go.drugbank.com/drugs/DB16249
    Investigational

    Naphthoquine is under investigation in clinical trial NCT01930331 (Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO).

  4. Drug

    LIS-1

    go.drugbank.com/drugs/DB18388
    Experimental

    LIS-1 is an immunoglobulin G (IgG) polyclonal antibody that binds to human T cells.

  5. Drug

    Cytochrome C

    go.drugbank.com/drugs/DB18543
    Investigational

    Cytochrome C is a hemeprotein that plays a role in the mitochondrial electron-transport chain.

  6. Drug

    RGG0853

    go.drugbank.com/drugs/DB18669
    Experimental

    RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.

  7. Drug

    Pimasertib

    go.drugbank.com/drugs/DB14904
    Investigational

    Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).

    Synonyms: N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide
  8. Drug

    Methopterin

    go.drugbank.com/drugs/DB16620
    Investigational

    Methopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.[A229843]

  9. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. The two synthetic peptide vaccine components...

  10. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically ...